The Technical AnalystExchange: EURONEXT Industry: Medical Devices
Sequana Medical NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.60% €1.660
America/New_York / 17 mai 2024 @ 11:28
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50.20 mill |
| EPS: | -1.320 |
| P/E: | -1.260 |
| Earnings Date: | May 23, 2024 |
| SharesOutstanding: | 30.24 mill |
| Avg Daily Volume: | 0.0967 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.260 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -1.260 | industry: PE 60.12 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€-0.989 (-159.55%) €-2.65 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 1.556 - 1.764 ( +/- 6.27%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €1.660 (-4.60% ) |
| Volume | 0.0614 mill |
| Avg. Vol. | 0.0967 mill |
| % of Avg. Vol | 63.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SEQUA.BR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SEQUA.BR
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.